Both Mersana Therapeutics Inc. (NASDAQ:MRSN) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mersana Therapeutics Inc.||48.56M||6.28||29.95M||-2.43||0.00|
|EyePoint Pharmaceuticals Inc.||6.94M||26.60||101.70M||-1.35||0.00|
Table 1 demonstrates Mersana Therapeutics Inc. and EyePoint Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.
Table 2 provides us the return on assets, net margins and return on equity of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Mersana Therapeutics Inc.||-61.68%||-110.4%||-49.8%|
|EyePoint Pharmaceuticals Inc.||-1,465.42%||-414.6%||-142.9%|
The current Quick Ratio of Mersana Therapeutics Inc. is 2.9 while its Current Ratio is 2.9. Meanwhile, EyePoint Pharmaceuticals Inc. has a Current Ratio of 2.6 while its Quick Ratio is 2.6. Mersana Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than EyePoint Pharmaceuticals Inc.
Institutional & Insider Ownership
Institutional investors owned 78.4% of Mersana Therapeutics Inc. shares and 62.3% of EyePoint Pharmaceuticals Inc. shares. Insiders owned roughly 0.1% of Mersana Therapeutics Inc.’s shares. Comparatively, 0.5% are EyePoint Pharmaceuticals Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Mersana Therapeutics Inc.||-37.91%||-4.15%||-18.7%||-68.3%||-74.65%||7.6%|
|EyePoint Pharmaceuticals Inc.||-2.21%||21%||28.64%||25%||150%||40.21%|
For the past year Mersana Therapeutics Inc. has weaker performance than EyePoint Pharmaceuticals Inc.
Mersana Therapeutics Inc. beats EyePoint Pharmaceuticals Inc. on 7 of the 10 factors.
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company’s pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.